Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Expression and purification of hepatitis C virus protease from clinical samples.

van der Helm L.

Methods Mol Biol. 2013;1030:119-27. doi: 10.1007/978-1-62703-484-5_10.

PMID:
23821264
2.

Immunoreactivity assessment of hepatitis C virus NS3 protease and NS5A proteins expressed in TOPO cloning system.

Alaee M, Rajabi P, Sharifi Z, Farajollahi MM.

J Microbiol Immunol Infect. 2014 Aug;47(4):282-91. doi: 10.1016/j.jmii.2012.08.016. Epub 2012 Oct 4.

3.

Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus.

Poliakov A, Hubatsch I, Shuman CF, Stenberg G, Danielson UH.

Protein Expr Purif. 2002 Aug;25(3):363-71.

PMID:
12182815
4.

Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex.

Sali DL, Ingram R, Wendel M, Gupta D, McNemar C, Tsarbopoulos A, Chen JW, Hong Z, Chase R, Risano C, Zhang R, Yao N, Kwong AD, Ramanathan L, Le HV, Weber PC.

Biochemistry. 1998 Mar 10;37(10):3392-401.

PMID:
9521660
5.

Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.

Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkühler C, De Francesco R.

J Virol. 1998 Aug;72(8):6758-69.

6.

Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3.

Butkiewicz N, Yao N, Zhong W, Wright-Minogue J, Ingravallo P, Zhang R, Durkin J, Standring DN, Baroudy BM, Sangar DV, Lemon SM, Lau JY, Hong Z.

J Virol. 2000 May;74(9):4291-301.

7.

Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.

Fatima K, Tahir M, Qadri I.

Virus Res. 2011 Sep;160(1-2):230-7. doi: 10.1016/j.virusres.2011.06.020. Epub 2011 Jul 2.

PMID:
21756947
8.

PCR-based in vitro synthesis of hepatitis C virus NS3 protease for rapid phenotypic resistance testing of protease inhibitors.

Qiao J, Yu J, Yang H, Wei H.

J Clin Microbiol. 2014 Apr;52(4):1139-45. doi: 10.1128/JCM.03257-13. Epub 2014 Jan 22.

9.

Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression.

An HY, Kim GN, Wu K, Kang CY.

Virus Res. 2013 Jan;171(1):168-77. doi: 10.1016/j.virusres.2012.11.007. Epub 2012 Nov 30.

PMID:
23207069
10.

Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system.

Hong Z, Ferrari E, Wright-Minogue J, Chase R, Risano C, Seelig G, Lee CG, Kwong AD.

J Virol. 1996 Jul;70(7):4261-8.

11.

Hepatitis C virus nonstructural 3 protein: recombinant NS3 protein of the Thai isolates as an antigen in a diagnostic assay.

Kanistanon D, Wongprompitak P, Dharakul T, Songsivilai S.

Asian Pac J Allergy Immunol. 2002 Sep;20(3):161-6.

12.

Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.

Lodrini S, Bagaglio S, Canducci F, De Mitri MS, Andreone P, Loggi E, Lazzarin A, Clementi M, Morsica G.

J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):198-204.

PMID:
14518724
13.

Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3.

Manabe S, Fuke I, Tanishita O, Kaji C, Gomi Y, Yoshida S, Mori C, Takamizawa A, Yosida I, Okayama H.

Virology. 1994 Feb;198(2):636-44.

PMID:
8291245
14.

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.

Sheaffer AK, Lee MS, Hernandez D, Chaniewski S, Yu F, Falk P, Friborg J, Zhai G, McPhee F.

Antivir Ther. 2011;16(5):705-18. doi: 10.3851/IMP1825.

PMID:
21817192
15.

Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.

Svarovskaia ES, Martin R, McHutchison JG, Miller MD, Mo H.

J Clin Microbiol. 2012 Oct;50(10):3267-74. doi: 10.1128/JCM.00838-12. Epub 2012 Jul 25.

16.

Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.

Mello IM, Thumann C, Schvoerer E, Soulier E, Pinho JR, Silvestre DA, Queiroz AT, Wolf P, Baumert TF, Keller FS, Pereira CA.

J Viral Hepat. 2009 Oct;16(10):732-7. doi: 10.1111/j.1365-2893.2009.01125.x. Epub 2009 Mar 25.

PMID:
19486468
17.

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.

Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H.

Antiviral Res. 2009 Feb;81(2):166-73. doi: 10.1016/j.antiviral.2008.11.002. Epub 2008 Dec 6.

PMID:
19063924
18.

Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.

Massariol MJ, Zhao S, Marquis M, Thibeault D, White PW.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):692-7. doi: 10.1016/j.bbrc.2009.11.122. Epub 2009 Nov 26.

PMID:
19944069
20.

Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.

Aparicio E, Franco S, Parera M, Andrés C, Tural C, Clotet B, Martínez MA.

J Virol. 2011 Jun;85(12):5961-9. doi: 10.1128/JVI.00308-11. Epub 2011 Apr 6.

Supplemental Content

Support Center